{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:18:40Z","timestamp":1758446320358,"version":"3.44.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40744-025-00786-2","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:00:58Z","timestamp":1752904858000},"page":"909-923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment"],"prefix":"10.1007","volume":"12","author":[{"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Urbanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Stigler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Truman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"9","key":"786_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global Prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). 2016;68(9):1320\u201331. https:\/\/doi.org\/10.1002\/acr.22831.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"786_CR2","unstructured":"NICE. National Institute for Health and Care Excellence: Clinical Guidelines. Spondyloarthritis in over 16s: diagnosis and management. National Institute for Health and Care Excellence (UK)Copyright \u00a9 National Institute for Health and Care Excellence 2017.; 2017."},{"issue":"1","key":"786_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-019-1927-6","volume":"21","author":"C L\u00f3pez-Medina","year":"2019","unstructured":"L\u00f3pez-Medina C, Dougados M, Ruyssen-Witrand A, Molt\u00f3 A. Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort. Arthritis Res Ther. 2019;21(1):139. https:\/\/doi.org\/10.1186\/s13075-019-1927-6.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"786_CR4","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s11136-018-1900-x","volume":"27","author":"YH Kwan","year":"2018","unstructured":"Kwan YH, Fong W, How P, et al. The impact of axial spondyloarthritis on quality of life (QoL): a comparison with the impact of moderate to end-stage chronic kidney disease on QoL. Qual Life Res. 2018;27(9):2321\u20137. https:\/\/doi.org\/10.1007\/s11136-018-1900-x.","journal-title":"Qual Life Res"},{"issue":"11","key":"786_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.200872","volume":"48","author":"E Mogard","year":"2021","unstructured":"Mogard E, Olofsson T, Bergman S, et al. Chronic pain and assessment of pain sensitivity in patients with axial spondyloarthritis: results from the SPARTAKUS Cohort. J Rheumatol. 2021;48(11):1672\u20139. https:\/\/doi.org\/10.3899\/jrheum.200872.","journal-title":"J Rheumatol"},{"issue":"1","key":"786_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13075-018-1626-8","volume":"20","author":"TW Swinnen","year":"2018","unstructured":"Swinnen TW, Westhovens R, Dankaerts W, de Vlam K. Widespread pain in axial spondyloarthritis: clinical importance and gender differences. Arthritis Res Ther. 2018;20(1):156. https:\/\/doi.org\/10.1186\/s13075-018-1626-8.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"786_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230268","volume":"15","author":"M Hebeisen","year":"2020","unstructured":"Hebeisen M, Micheroli R, Scherer A, et al. Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. PLoS ONE. 2020;15(3): e0230268. https:\/\/doi.org\/10.1371\/journal.pone.0230268.","journal-title":"PLoS ONE"},{"issue":"1","key":"786_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"786_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","volume":"56","author":"X Baraliakos","year":"2017","unstructured":"Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology. 2017;56(1):95\u2013102. https:\/\/doi.org\/10.1093\/rheumatology\/kew367.","journal-title":"Rheumatology"},{"issue":"8","key":"786_CR10","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207897.","journal-title":"Ann Rheum Dis"},{"key":"786_CR11","doi-asserted-by":"publisher","first-page":"Cd010952","DOI":"10.1002\/14651858.CD010952.pub2","volume":"7","author":"FP Kroon","year":"2015","unstructured":"Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;7:Cd010952. https:\/\/doi.org\/10.1002\/14651858.CD010952.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"786_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-023-03051-5","volume":"25","author":"J Braun","year":"2023","unstructured":"Braun J, Blanco R, Marzo-Ortega H, et al. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2023;25(1):80. https:\/\/doi.org\/10.1186\/s13075-023-03051-5.","journal-title":"Arthritis Res Ther"},{"issue":"10349","key":"786_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10349):369\u201379. https:\/\/doi.org\/10.1016\/s0140-6736(22)01212-0.","journal-title":"Lancet"},{"issue":"4","key":"786_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/ard-2022-223595","volume":"82","author":"D van der Heijde","year":"2023","unstructured":"van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023;82(4):515\u201326. https:\/\/doi.org\/10.1136\/ard-2022-223595.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"786_CR15","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/acr.23465","volume":"70","author":"M Alazmi","year":"2018","unstructured":"Alazmi M, Sari I, Krishnan B, Inman RD, Haroon N. Profiling response to tumor necrosis factor inhibitor treatment in axial spondyloarthritis. Arthritis Care Res (Hoboken). 2018;70(9):1393\u20139. https:\/\/doi.org\/10.1002\/acr.23465.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-0969-2","volume":"18","author":"A Ciurea","year":"2016","unstructured":"Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18:1\u20138.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"786_CR17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81(11):1515\u201323. https:\/\/doi.org\/10.1136\/ard-2022-222608.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"786_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejr.2022.08.003","volume":"45","author":"S Almousa","year":"2023","unstructured":"Almousa S, Alshamaa N, Wannous H, Khder K, Qasem H. Gender-related differences in axial spondyloarthritis (axSpA) patients. Egypt Rheumatolog. 2023;45(1):13\u20136. https:\/\/doi.org\/10.1016\/j.ejr.2022.08.003.","journal-title":"Egypt Rheumatolog"},{"issue":"6","key":"786_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-018-0744-2","volume":"20","author":"T Rusman","year":"2018","unstructured":"Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018;20(6):35. https:\/\/doi.org\/10.1007\/s11926-018-0744-2.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"786_CR20","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s10067-022-06228-6","volume":"41","author":"H Marzo-Ortega","year":"2022","unstructured":"Marzo-Ortega H, Navarro-Comp\u00e1n V, Akar S, Kiltz U, Clark Z, Nikiphorou E. The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis. Clin Rheumatol. 2022;41(11):3573\u201381. https:\/\/doi.org\/10.1007\/s10067-022-06228-6.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"786_CR21","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372. https:\/\/doi.org\/10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"786_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy Jd, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"786_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8): e010352. https:\/\/doi.org\/10.1136\/bmjopen-2015-010352.","journal-title":"BMJ Open"},{"issue":"4","key":"786_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejpain.2003.09.004","volume":"8","author":"F Salaffi","year":"2004","unstructured":"Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283\u201391. https:\/\/doi.org\/10.1016\/j.ejpain.2003.09.004.","journal-title":"Eur J Pain"},{"key":"786_CR25","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of Conduct. 06 December 2022. Updated August 2022. https:\/\/www.ephmra.org\/code-conduct-aer. Accessed 31 Jan 2025."},{"issue":"4","key":"786_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40744-024-00685-y","volume":"11","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Saffore CD, Collins EB, Parikh B, Ye X, Walsh JA. Comparative efficacy of advanced therapies in the treatment of radiographic axial spondyloarthritis or ankylosing spondylitis as evaluated by the ASDAS low disease activity criteria. Rheumatol Ther. 2024;11(4):989\u201399. https:\/\/doi.org\/10.1007\/s40744-024-00685-y.","journal-title":"Rheumatol Ther"},{"key":"786_CR27","unstructured":"Enbrel is First Biologic to Receive FDA Approval for the Treatment of Ankylosing Spondylitis. 2003. https:\/\/www.amgen.com\/newsroom\/press-releases\/2003\/07\/enbrel-is-first-biologic-to-receive-fda-approval-for-the--treatment-of-ankylosing-spondylitis. Accessed 15 Apr 2025."},{"key":"786_CR28","unstructured":"Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US. Novartis Media Relations; 2016. https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-two-new-fda-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis-us. Accessed 15 Apr 2025."},{"key":"786_CR29","unstructured":"Etanercept Product Approval Information. U.S. Food & Drug Administration; 1998. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=103795. Accessed 21 Mar 2025."},{"key":"786_CR30","unstructured":"Infliximab Product Approval Information. U.S. Food & Drug Administration; 1998. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed 21 Mar 2025."},{"key":"786_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002049","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Ostor AJK, Mease PJ, et al. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open. 2022. https:\/\/doi.org\/10.1136\/rmdopen-2021-002049.","journal-title":"RMD Open"},{"issue":"3","key":"786_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40744-023-00536-2","volume":"10","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Baraliakos X, Magrey M, et al. Effect of upadacitinib on disease activity, pain, fatigue, function, health-related quality of life and work productivity for biologic refractory ankylosing spondylitis. Rheumatol Ther. 2023;10(3):679\u201391. https:\/\/doi.org\/10.1007\/s40744-023-00536-2.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"786_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/ard.2011.154799","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71(5):661\u20137. https:\/\/doi.org\/10.1136\/ard.2011.154799.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"786_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/acr.24517","volume":"74","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Conaghan PG, Gossec L, et al. Secukinumab and sustained reduction in fatigue in patients with ankylosing spondylitis: long-term results of two phase III randomized controlled trials. Arthritis Care Res (Hoboken). 2022;74(5):759\u201367. https:\/\/doi.org\/10.1002\/acr.24517.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10217","key":"786_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(19)32971-x","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364. https:\/\/doi.org\/10.1016\/s0140-6736(19)32971-x.","journal-title":"Lancet"},{"issue":"8","key":"786_CR36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/acr2.11669","volume":"6","author":"F Van den Bosch","year":"2024","unstructured":"Van den Bosch F, Deodhar A, Poddubnyy D, et al. Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, phase 3 trial. ACR Open Rheumatol. 2024;6(8):470\u201380. https:\/\/doi.org\/10.1002\/acr2.11669.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"786_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13075-023-03128-1","volume":"25","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, van der Heijde D, Sieper J, et al. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. Arthritis Res Ther. 2023;25(1):172. https:\/\/doi.org\/10.1186\/s13075-023-03128-1.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"786_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13075-024-03441-3","volume":"27","author":"F Van den Bosch","year":"2025","unstructured":"Van den Bosch F, Deodhar A, Poddubnyy D, et al. Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Res Ther. 2025;27(1):23. https:\/\/doi.org\/10.1186\/s13075-024-03441-3.","journal-title":"Arthritis Res Ther"},{"key":"786_CR39","doi-asserted-by":"publisher","first-page":"1341981","DOI":"10.3389\/fimmu.2024.1341981","volume":"15","author":"C Selmi","year":"2024","unstructured":"Selmi C, Chimenti MS, Novelli L, et al. Pain in axial spondyloarthritis: role of the JAK\/STAT pathway. Front Immunol. 2024;15:1341981. https:\/\/doi.org\/10.3389\/fimmu.2024.1341981.","journal-title":"Front Immunol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00786-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00786-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00786-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T10:28:38Z","timestamp":1758364118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00786-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00786-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Molly Edwards, Isabel Truman, and Sophie Barlow are employees of Adelphi Real World. Christopher D. Saffore, Xiaolan Ye, Jamie Urbanik, and Jayne Stigler are employees of AbbVie Inc. and may hold stock or stock options.\u00a0Xenofon Baraliakos has received grant\/research support from AbbVie and Novartis; consulting fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB Pharma; speakers\u2019 bureau fees from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, and UCB Pharma; is an editorial board member of the\u00a0Annals of Rheumatic Diseases; is the ASAS President; and is the EULAR President-elect. Atul Deodhar has received grant\/research support from AbbVie, BMS, Celgene, Lilly, MoonLake, Novartis, Pfizer, and UCB Pharma; and honoraria or consultation fees from AbbVie, BMS, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Using a checkbox, patients provided informed consent to take part in the survey. No identifiable protected health information was extracted during the survey. Data were collected in such a way that patients and physicians could not be identified directly, with data aggregated before being shared with the subscriber and\/or for publication. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such did not require ethics committee approval []. This research was submitted to the Pearl Institutional Review Board (study protocol nos. AG8929 for data from March\u2013November 2021 and AG9361 for data from June 2023\u2013June 2024) and deemed to be exempt from ethical approval. This research followed the principles of the Helsinki Declaration of 1964 and subsequent amendments. In addition, each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 and Health Information Technology for Economic and Clinical Health Act legislation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}